P01834 (IGKC_HUMAN) Homo sapiens (Human)
Immunoglobulin kappa constant UniProtKBProtein AtlasInterProInteractive Modelling
107 aa; Sequence (Fasta) ;
1 identical sequence: Cyprinus carpio: A0A8C2JGN2
Available Structures
86 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| Crystal structure of broadly and potently neutralizing antibody VRC08 in complex with HIV-1 clade A… |
Heteromer P01857; Q8JDI3; | 100 | 11×NAG; 2×BU3; | |||
| Crystal Structure of a Broadly Neutralizing Anti-HIV-1 Antibody in Complex with a Peptide Mimotope |
Heteromer P0DOX5; | 99.06 | 8×GOL; 4×SO4; 1×CXS; 1×K; | |||
| Trastuzumab Fab v3 |
Heteromer P02976; Q51918; S6B291; | 100 | ||||
| Trastuzumab Fab v3 with 5-diphenyl meditope variant |
Heteromer P02976; Q51918; Q6GMX6; | 100 | ||||
| Crystal structure of human anti-tau antibody CBTAU-27.1 |
Heteromer P01857; | 100 | 2×GOL; | |||
| 48G7 HYBRIDOMA LINE FAB COMPLEXED WITH HAPTEN 5-(PARA-NITROPHENYL PHOSPHONATE)-PENTANOIC ACID |
Heteromer P01857; | 100 | 1×NPE; | |||
| Trastuzumab Fab v3 in complex with CQFDLSTRRLKC |
Heteromer P02976; Q51918; S6B291; | 100 | ||||
| Trastuzumab Fab v3 in complex with 5-phenyl meditope variant |
Heteromer P02976; Q51918; Q6GMX6; | 100 | ||||
| Neuropilin-1 b1 Domain in Complex with a VEGF-Blocking Fab |
Heteromer O14786; P01857; | 100 | 3×EDO; | |||
| Crystal structure of a humanised 3D6 Fab bound to amyloid beta peptide |
Heteromer P01857; P05067; | 100 | ||||
| Crystal structure of broadly and potently neutralizing antibody VRC08C in complex with HIV-1 clade … |
Heteromer P01857; Q8JDI3; | 100 | 11×NAG; | |||
| ANTIBODY GNC92H2 BOUND TO LIGAND |
Heteromer P01857; | 100 | 1×COC; | |||
| HIV-1 gp120 Envelope Glycoprotein Complexed with the Broadly Neutralizing CD4-Binding-Site Antibody… |
Heteromer P35961; | 99.06 | 13×NAG; | |||
| Crystal structure of a Fab binding to extracellular domain 5 of Cadherin-6 |
Heteromer P55285; S6B291; | 100 | 2×A2G; | |||
| Structure of NIH45-46 Fab in complex with gp120 of 93TH057 HIV |
Heteromer A0A0M3KKW9; P01857; | 100 | 1×NAG; 1×FLC; 6×NAG; 1×CL; | |||
| IGG FAB (HUMAN IGG1, KAPPA) CHIMERIC FRAGMENT (CBR96) COMPLEXED WITH LEWIS Y NONOATE METHYL ESTER |
Heteromer | 100 | 1×NAG; 1×NON; | |||
| STRUCTURE OF UNCOMPLEXED FAB COMPARED TO COMPLEX (1CLY, 1CLZ) |
Heteromer | 100 | 1×SO4; | |||
| Crystal structure of NIH45-46 Fab |
Heteromer P01857; | 100 | 3×GOL; 1×SO4; 1×NAG; | |||
| Crystal Structure of Chimeric Antibody C2H7 Fab in complex with a CD20 Peptide |
Heteromer P01857; P11836; | 100 | ||||
| FREE AND LIGANDED FORM OF AN ESTEROLYTIC CATALYTIC ANTIBODY |
Heteromer P01857; | 100 | ||||
| CRYSTAL STRUCTURE OF THE INTACT HUMAN IGG B12 WITH BROAD AND POTENT ACTIVITY AGAINST PRIMARY HIV-1 … |
Heteromer P01857; | 99.06 | 1×NAG; 1×NAG; | |||
| Structure of P. magnus protein L bound to a human IgM Fab. |
Heteromer P01871; Q51918; | 100 | 2×IMD; | |||
| STRUCTURE OF A HUMAN MONOCLONAL ANTIBODY FAB FRAGMENT AGAINST GP41 OF HUMAN IMMUNODEFICIENCY VIRUS … |
Heteromer P01857; | 100 | ||||
| Crystal structure of K63-specific fab Apu2.16 bound to K63-linked di-ubiquitin |
Heteromer P01857; P0CG48; | 100 | ||||
| Anti-beta-amyloid antibody c706 fab in space group c2 |
Heteromer P01857; | 100 | ||||
| Crystal structure analysis of anti-HIV-1 V3-Fab F425-B4e8 in complex with a V3-peptide |
Heteromer P01859; P05877; | 100 | 1×NAG; 4×ZN; 4×CL; | |||
| Neuropilin-2 a1a2b1b2 Domains in Complex with a Semaphorin-Blocking Fab |
Heteromer O60462; P01857; | 100 | ||||
| Structure of human B-cell antigen receptor of the IgM isotype |
Heteromer P01871; P11912; P40259; | 100 | 14×NAG; | |||
| Cryo-EM structure of Her2 extracellular domain-Trastuzumab Fab-Pertuzumab Fab complex |
Heteromer P04626; P0DOX5; Q6GMX6; | 100 | 1×NAG; 5×NAG; | |||
| S protein of SARS-CoV-2 in complex bound with P5A-2F11_2B |
Heteromer A0A5C2G1U0; P0DP01; P0DTC2; V9HW68; | 100 | 21×NAG; 2×NAG; 28×NAG; | |||
| CryoEM structure of Hantavirus ANDV Gn(H) protein complex with 2Fabs ANDV-5 and ANDV-34 |
Heteromer P0DOX5; Q9E006; | 99.06 | ||||
| S protein of SARS-CoV-2 in complex bound with P5A-2F11_3B |
Heteromer A0A5C2G1U0; P0DP01; P0DTC2; V9HW68; | 100 | 22×NAG; 3×NAG; 27×NAG; | |||
| Structure of IgE bound to the ectodomain of FceRIa |
Heteromer P01854; P12319; | 99.06 | 2×NAG; 2×NAG; 3×NAG; 2×NAG; | |||
| Anti-HIV-1 Fab 2G12 + Man1-2 re-refinement |
Heteromer P01857; | 100 | 1×MAN; 1×BEZ; 1×GOL; 1×MAN; | |||
| Crystal structure of the major grass pollen allergen Phl p 2 in complex with its specific IgE-Fab |
Heteromer P01857; P43214; | 100 | ||||
| Crystal structure of the LT3015 antibody Fab fragment in complex with lysophosphatidic acid (14:0) |
Heteromer Q6N089; | 100 | 1×NKN; | |||
| Crystal structure of human anti-tau antibody CBTAU-27.1 Fab in complex with a human tau peptide |
Heteromer A0A2K5IAM2; P01857; | 100 | ||||
| Crystal structure of the humanized apo LT3015 anti-lysophosphatidic acid antibody Fab fragment |
Heteromer Q6N089; | 100 | 2×SO4; 1×PGE; | |||
| Anti-HIV-1 Fab 2G12 re-refinement |
Heteromer P0DOX5; | 100 | 5×SO4; | |||
| Crystal structure of anti-human cytomegalovirus antibody 8f9 plus gB peptide |
Heteromer P01857; P13201; | 100 | 2×GOL; | |||
| Crystal Structure of mid-region amyloid beta capture by solanezumab |
Heteromer P01857; P05067; | 100 | ||||
| Inhibiting Alternative Pathway Complement Activation by Targeting the Exosite on Factor D |
Heteromer P00746; P01857; | 100 | ||||
| Crystal structure of the LT3015 antibody Fab fragment in complex with lysophosphatidic acid (18:2) |
Heteromer Q6N089; | 100 | 1×18L; | |||
| IGG FAB FRAGMENT (CD25-BINDING) |
Heteromer | 100 | ||||
| Crystal structure of broadly neutralizing antibody CR8043 |
Heteromer S6C4S0; | 100 | 2×PEG; | |||
| Crystal structure of SARS-CoV-2 spike stem fusion peptide in complex with neutralizing antibody COV… |
Heteromer P0DOX5; P0DTC2; | 100 | ||||
| Anti-HIV-1 Fab 2G12 + Man9 re-refinement |
Heteromer P0DOX5; | 100 | 2×NAG; | |||
| Crystal Structure of Broadly Neutralizing Antibody CH03, Isolated from Donor CH0219, in Complex wit… |
Heteromer P44815; S6BGE0; W6ICC0; | 100 | 1×NAG; 1×NAG; 5×NAG; 2×NAG; 2×NAG; 3×ZN; 1×NAG; | |||
| Crystal structure of broadly and potently neutralizing antibody VRC06B in complex with HIV-1 clade … |
Heteromer P01857; Q0ED31; | 100 | 1×NAG; 6×NAG; | |||
| Crystal Structure of Broadly Neutralizing Antibody CH04, Isolated from Donor CH0219, in Complex wit… |
Heteromer P44815; Q4QX31; | 100 | 1×NAG; 1×NAG; 1×NAG; | |||
| BG505 SOSIP.664 in complex with broadly neutralizing antibodies BG1 and 8ANC195 |
Heteromer Q2N0S6; Q8TCD0; S6B291; | 100 | 10×NAG; 18×NAG; 5×NAG; 3×NAG; 7×NAG; 1×NAG; 13×NAG; | |||
| AD related murine antibody Fragment |
Heteromer P01647; P01808; P01857; | 100 | ||||
| Crystal structure of 1E9 LeuH47Trp/ArgH100Trp, an engineered Diels-Alderase Fab with nM steroid-bin… |
Heteromer P01631; P01857; | 100 | 11×SO4; 1×TRS; | |||
| Structure of an HIV epitope scaffold in complex with neutralizing antibody b12 Fab |
Heteromer | 99.05 | 4×GOL; | |||
| DIELS ALDER CATALYTIC ANTIBODY GERMLINE PRECURSOR |
Heteromer | 100 | ||||
| DIELS ALDER CATALYTIC ANTIBODY WITH TRANSITION STATE ANALOGUE |
Heteromer | 100 | 2×CD; 1×FRA; | |||
| Crystal structure of the 1E9 LeuH47Trp/ArgH100Trp Fab 5-beta-androstane-3,17-dione complex |
Heteromer P01631; P01857; | 100 | 23×SO4; 1×ANO; | |||
| Structure of cetuximab with aminoheptanoic acid-linked N-(3-hydroxypropyl)-L-arginine meditope vari… |
Heteromer S6B291; | 100 | 1×SO4; | |||
| Structure of cetuximab with aminoheptanoic acid-linked N-(3-aminopropyl)-L-arginine meditope variant |
Heteromer S6B291; | 100 | ||||
| Structure of cetuximab with aminoheptanoic acid-linked N-carboxyethylarginine meditope variant |
Heteromer S6B291; | 100 | 1×SO4; | |||
| Structure of cetuximab with aminoheptanoic acid-linked n-octylarginine meditope variant |
Heteromer S6B291; | 100 | 1×SO4; | |||
| Structure of cetuximab with aminoheptanoic acid-linked n-butylarginine meditope variant |
Heteromer S6B291; | 100 | 1×SO4; | |||
| Crystal structure of anti-human cytomegalovirus antibody 8F9 |
Heteromer P01857; | 100 | ||||
| Crystal structure of isolated domain III of the extracellular region of the epidermal growth factor… |
Heteromer P00533; P01857; | 100 | 1×NAG; 1×NAG; 2×NAG; 1×SO4; | |||
| Crystal structure of K63-specific fab Apu.3A8 bound to K63-linked di-ubiquitin |
Heteromer P0CG48; | 100 | ||||
| Crystal structure of the 1E9 LeuH47Trp/ArgH100Trp Fab progesterone complex |
Heteromer P01631; P01857; | 100 | 13×SO4; 1×STR; | |||
| Crystal structure the Fab fragment of matuzumab (Fab72000) in complex with domain III of the extrac… |
Heteromer P00533; P01857; | 100 | 4×NAG; 1×BMA; | |||
| Crystal Structure of the Human Fab VRC38.01, an HIV-1 V1V2-Directed Neutralizing Antibody Isolated … |
Heteromer Q6N089; | 100 | ||||
| UNLIGANDED GERMLINE PRECURSOR OF AN OXY-COPE CATALYTIC ANTIBODY |
Heteromer P01857; | 100 | 3×CD; | |||
| CONFORMATION EFFECTS IN BIOLOGICAL CATALYSIS INTRODUCED BY OXY-COPE ANTIBODY MATURATION |
Heteromer P01857; | 100 | 4×CD; 1×HOP; | |||
| Crystal structure of MJ5 Fab, a germline antibody variant of anti-human cytomegalovirus antibody 8f9 |
Heteromer P01857; P04433; | 100 | ||||
| Neuropilin-2 a1a2b1b2 Domains in Complex with a Semaphorin-Blocking Fab |
Heteromer O60462; P01857; | 100 | 4×NAG; | |||
| UNLIGANDED MATURE OXY-COPE CATALYTIC ANTIBODY |
Heteromer P01857; | 100 | 1×CD; | |||
| Crystal structure of the Fab fragment of therapeutic antibody Basiliximab in complex with IL-2Ra (C… |
Heteromer P01589; | 100 | 1×NAG; | |||
| Crystal structure of the trimeric prefusion Ebola virus glycoprotein in complex with a neutralizing… |
Heteromer P01857; Q05320; | 99.04 | 2×NAG; 2×NAG; 1×NAG; 1×NAG; | |||
| Crystal structure of broadly neutralizing antibody CR8043 bound to H3 influenza hemagglutinin |
Heteromer Q91MA7; S6C4S0; | 100 | 6×NAG; 8×NAG; | |||
| Crystal structure BG505 SOSIP gp140 HIV-1 Env trimer bound to broadly neutralizing antibodies PGT12… |
Heteromer P01857; Q2N0S6; S6B291; | 100 | 12×NAG; 6×NAG; 3×NAG; 3×NAG; 3×NAG; 9×NAG; 3×NAG; 3×NAG; 18×NAG; 3×SO4; | |||
| STRUCTURE OF THE ANTIBODY 7B2 THAT CAPTURES HIV-1 VIRIONS |
Heteromer P04578; S6B291; | 100 | ||||
| Crystal structure of the NK1 domain of HGF in complex with anti-HGF monoclonal antibody SFN68. |
Heteromer P14210; U3KM01; | 100 | ||||
| Crystal structure of HLA-B*57:01.I80N |
Heteromer P01889; P61769; | 100 | ||||
| KIR3DL1 in complex with HLA-B*5701 |
Heteromer P01889; P43629; P61769; | 100 | 3×NAG; | |||
| KIR3DL1 in complex with HLA-B*57:01.I80T |
Heteromer P01889; P43629; P61769; | 100 | 3×NAG; | |||
| Crystal structure of HLA-B*57:01.I80N.L82R.R83G |
Heteromer P01889; P61769; | 100 | ||||
| KIR3DL1*005 in complex with HLA-B*57:01 |
Heteromer P01889; P43629; P61769; | 100 | 3×NAG; | |||
| Crystal Structure of HLA-B*5701, presenting the self peptide, LSSPVTKSF |
Heteromer P01889; P61769; | 100 | 4×GOL; | |||
| KIR3DL1*015 in complex with HLA-B*57:01 |
Heteromer P01889; P43629; P61769; | 100 | 3×NAG; | |||
1 SWISS-MODEL model
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 8dao.1.D | monomer | 0.89 | 100.00 | |||